GENEART joins Quiagen Initiative pAlliance
The company Geneart GmbH, formed in 1999 through the University of Regensburg, has specialized in the production of synthetic genes. These are used in particular in the development of new vaccines and medicines. Synthetic genes can be tailor-made and optimized by the pharmaceutical and biotechnology industry to the customers’ needs.
Qiagen N.V., a holding company in the Netherlands with its headquarters in Venlo, is a leading manufacturer of innovative products and technology for the separation, purification and use of nucleic acids, the material from which genetic inheritance is derived, and of proteins. The company employs 1400 people worldwide and is listed on the stock exchange in Frankfurt.
This alliance, initiated by Qiagen, involves strategic cooperation for the manufacturing of plasmid DNA in accordance with the guidelines of the Medicines Act. A plasmid is a ring-formed DNA molecule that can be isolated relatively easily. In fact via this process DNA-based vaccines and therapeutic agents can be developed. These are viewed as innovative types of treatment with considerable potential for combating tumors and infectious diseases such as HIV (AIDS) and leukemia, which to date have been incurable or very difficult to cure. The alliance combines many years of experience in the production of DNA for clinical studies in the USA, Japan and Europe. Further partners in the alliance are Strathmann Biotech AG (Hamburg) and Newlab Bioquality AG (Erkrath).
For more information see: